CD25: A potential tumor therapeutic target

CD25 is the alpha-chain of the heterotrimer IL-2 receptor. CD25 is expressed on the surface of both immune and non-immune cells with different frequencies. For cancers, CD25 is expressed at high levels in many types of hematological malignancies, but at low levels in most solid tumors. CD25 is also highly expressed in activated circulating immune cells and regulatory T cells (Tregs). Infiltration of Tregs in the tumor microenvironment can lead to an imbalanced ratio of effector T cells (Teffs) and Tregs, which is associated with the progression of cancers. A rescued Teff/Treg cell ratio indicates an efficient anti-tumor response to immunotherapy. CD25 as a potential target for the depletion of Tregs is critical in developing new immunotherapeutic strategies. Few articles have summarized the relationships between CD25 and tumors, or the recent progress of drugs targeting CD25. In this paper, we will discuss the structures of IL-2 and IL-2R, the biological function of CD25 and its important role in tumor therapy. In addition, the latest research on drugs targeting CD25 has been summarized, providing guidance for future drug development.

Automated summary

CD25 is the alpha-chain of the heterotrimer IL-2 receptor, expressed on the surface of immune and non-immune cells with different frequencies. Its high expression in hematological malignancies and activated immune cells indicates its potential as a target for immunotherapy. The imbalanced ratio of effector T cells and regulatory T cells caused by Tregs infiltration in tumor microenvironment is associated with cancer progression. This paper summarizes the relationship between CD25 and tumors and discusses its important role in tumor therapy, as well as the recent progress of drugs targeting CD25.